<DOC>
	<DOCNO>NCT01948401</DOCNO>
	<brief_summary>This interventional , open study evaluate clinical data relation biomarkers patient 12 75 year age severe oral corticosteroid ( OCS ) - dependent asthma . Patients uncontrolled asthma offer additional escalation OCS dose 0.5 mg/kg 7 day . Patients enrol study would eligible enrolled future placebo-controlled intervention study design measure steroid-sparing effect lebrikizumab .</brief_summary>
	<brief_title>A Study Measure Serum Periostin , Asthma-Related Biomarkers Response Prednisolone Adult Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Adult adolescent patient , &gt; /=12 &lt; /=75 year age time inform consent Severe asthma ( define GINA step 5 classification asthma severity ) detail systematic assessment ( BTS UK Difficult Asthma Network assessment model [ Heaney et al 2010 ] equivalent ) followup asthma specialist least six month History asthma treatment high dos inhale corticosteroid ( ICS ) ( &gt; /=1500 mcg beclomethasone dipropionate daily , equivalent ) longacting beta2 agonist ( LABAs ) , without additional controller , least six month Screening Chronic treatment maintenance oral corticosteroid ( OCS ) least six month time informed consent ; ( baseline OCS dose : adult 10 40 mg/day , adolescents 5 40 mg/day daily dose equivalent ) Compliance OCS therapy base prior detectable level serum prednisolone , cortisol suppression , observation Cushingoid appearance consistent regular systemic steroid use Diagnosis refractory asthma ( Heaney et al 2010 ) OCS dependence minimal effective maximum tolerate dose Confirmed ( chest xray ) absence significant lung disease Documented history bronchodilator reversibility response &gt; /=12 % &gt; /=200 mL within past 12 month time inform consent Baseline FEV1 &lt; /=39 % predict Asthma exacerbation ( define protocol ) within 28 day time informed consent Screening Major episode infection require admission hospital &gt; /=24 hour treatment intravenous antibiotic within 28 day time informed consent Screening require treatment oral antibiotic within 14 day time informed consent Screening Active parasitic infection Listeria monocytogenes infection within 6 month time inform consent For adult active tuberculosis ( TB ) require treatment within 12 month time inform consent ( patient also require recurrence symptom 12 month follow completion TB treatment ) , adolescents history active TB require treatment Known history severe clinically significant immunodeficiency Evidence acute chronic hepatitis know liver cirrhosis Inadequate liver function Diagnosis history malignancy , current investigation possible malignancy Other clinically significant medical disease uncontrolled despite treatment likely , opinion investigator , require change therapy affect ability participate study Current smoker former smoker smoke history &gt; 15 packyears Current use immunomodulatory/immunosuppressive therapy past use within three month five drug halflives ( whichever longer ) time informed consent Use biologic therapy ( include omalizumab ) time 4 month time inform consent History anaphylaxis omalizumab treatment history anaphylaxis therapeutic biological agent Use zileuton roflumilast time two month time inform consent Initiation change allergen immunotherapy within three month time inform consent Treatment investigational agent within 30 day inform consent 5 halflives investigational agent , whichever longer Pregnant lactate woman Body mass index ( BMI ) &gt; 38 kg/m2 Body weight &lt; 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>